Anna Donald on

The summer witnessed another episode in the ongoing ‘rationing’ saga about NHS provision of the Alzheimer drugs rivastigmine, donepezil, and galantamine. The High Court upheld the substance of NICE’s guidance, which means that these drugs continue to be recommended only for people with ‘moderate’ Alzheimer’s.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here